共 50 条
The role of proteinuria, paricalcitol and vitamin D in the development of post-transplant diabetes mellitus
被引:3
|作者:
Dedinska, I
[1
,2
,3
]
Laca, L.
[1
,2
,3
]
Miklusica, J.
[1
,2
,3
]
Palkoci, B.
[1
,2
,3
]
Skalova, P.
[1
,2
,3
]
Kantarova, D.
[3
,4
]
Galajda, P.
[3
,4
]
Mokan, M.
[3
,4
]
机构:
[1] Univ Hosp Martin, Dept Surg, Kollarova 2, SK-03601 Martin, Slovakia
[2] Univ Hosp Martin, Transplantat Ctr, Kollarova 2, SK-03601 Martin, Slovakia
[3] Comenius Univ, Jessenius Med Fac, Martin, Slovakia
[4] Univ Hosp Martin, Dept Internal Dis 1, Martin, Slovakia
来源:
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY
|
2018年
/
119卷
/
07期
关键词:
post-transplant diabetes mellitus;
proteinuria;
vitamin D;
paricalcitol;
kidney transplantation;
CARDIOVASCULAR-DISEASE;
25-HYDROXYVITAMIN D;
D SUPPLEMENTATION;
KIDNEY-DISEASE;
RISK-FACTORS;
TRANSPLANTATION;
METAANALYSIS;
ASSOCIATION;
RECIPIENTS;
FAILURE;
D O I:
10.4149/BLL_2018_073
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
INTRODUCTION: Post-transplant diabetes mellitus (PTDM) occurs most frequently during the first year after transplantation. We focused on parameters of calcium-phosphate metabolism and proteinuria as possible new risk factors for PTDM after kidney transplantation. MATERIALS AND METHODS: We have prospectively identified risk factors for post-transplant diabetes mellitus with follow-up of 12 months in a set of 167 patients after kidney transplantation. Patients with diabetes mellitus type 1 and type 2 as well as patients using ciclosporin A or mTOR inhibitor have been excluded from the monitoring. From the perspective of immunosuppression it was a homogeneous set of patients. RESULTS: We identified the following independent risk factors for PTDM in our set: average proteinuria > 0.300 g/24 h (HR 3.0785, (95 % CI 1.6946-5.5927), p = 0.0002), level of vitamin D <20 ng/ml (HR 5.4517, (95 % CI 2.3167-11.8209), p < 0.0001) baseline serum level of phosphorus >1.45 mmol/l (HR0.0821, (95 % CI 0.0042-1.5920), p = 0.0439). The lowest occurrence of PTDM and proteinuria was recorded in patients whose treatment included paricalcitol (p < 0.0001) and these patients had at the same time the highest level of vitamin D (p < 0.0001). CONCLUSION: Deficit of vitamin D, proteinuria and hyperphosphatemia have been independent risk factors for the development of PTDM in our set. We identified the usage of paricalcitol as protective factor with regard to the PTDM development (Tab. 6, Fig. 4, Ref. 29). Text in PDF www.elis.sk.
引用
收藏
页码:401 / 407
页数:7
相关论文